DNA Immune Antibody Preparation Service-Tekbiotech-Yeast Display Service,Phage display technology

Services

Inquiry and ordering

Name*
Phone*
Email*
Product*
Content*

DNA Immune Antibody Preparation Service

DNA immunization is a technologically advanced method for efficiently inducing antibody and T-cell immune responses against a wide range of pathogens and for efficiently inducing high-quality polyclonal antibody responses in immunized animal or human sera with high conformational specificity and high affinity. Unlike conventional immunization methods, DNA immunization allows the host to produce target antigens in vivo with common post-transcriptional modifications that maintain a greater degree of original structure, bypassing the time-consuming process of synthesizing and purifying immunogens (e.g., peptides and recombinant proteins.) DNA immunization properties contribute to the generation of high-affinity antibodies against the target antigens in their natural conformation, which is also a key feature for the development of therapeutic antibodies. Also, this approach is ideal for developing antibodies against membrane proteins or other challenging antigens and antibodies. In addition, DNA immunization is a new tool in the early stages of immunotherapy and DNA vaccine development.

DNA immunization.jpg

Tek Biotech is able to provide DNA immunoantibody preparation services for a wide range of antigens (including but not limited to PTM proteins, intracellular proteins, and secretory proteins). Based on the hybridoma fusion and screening technology, Tek Biotech is able to provide a series of therapeutic biomolecule immuno-antibody preparation services, including but not limited to VHH nano-antibody, scFv antibody, Fab antibody, DNA immuno-antibody and other preparation services. After 10 years of development, Tek Biotech has established a comprehensive hybridoma fusion and screening platform, and is capable of providing a series of high-quality DNA immunoantibody preparation services based on hybridoma fusion and screening technology platform. In addition, Tek Biotech has one-stop technical services including gene synthesis and modification, AAV vector construction, animal immunization, hybridoma cell fusion and screening, antibody production, etc., and many downstream supporting services such as antigen-antibody binding assay, antigen-antibody BLI affinity determination, antibody cell line validation, etc., which can provide strong support for the R&D and production of antibody drugs for our customers.

█ Mechanisms of Immune Response Induced by DNA Immunization

Induction Mechanism	Details
Direct transfection of Somatic Cells	By transferring exogenous DNA molecules directly into the animal, muscle cells will be activated to produce MHC class I molecules, thus inducing an immune response in the body
Direct Transfection of Specialized Antigen-presenting Cells	A small number of dedicated APCs can be transfected directly at the injection site to produce endogenous proteins for complete endogenous antigen delivery via MHC I and MHC II molecules.
Apoptosis-like Mechanism	The target antigen or the recombinant plasmid sequence expressing the target antigen has transduction properties of its own.

█ Mode of Delivery of DNA Immunization

Transmission Method	Targeted Antigen Type
Gene Gun	Single transmembrane protein
	Intracellular protein
	Viral capsid protein
Intramuscular Injection	Bacterial toxin
	7 times transmembrane proteins
	Viral capsid protein
	Secreted proteins, enzymes
Intradermal Injection	Single transmembrane protein
	Extracellular matrix and plasma
	Glycoprotein
Electrical Pulse Stimulation After Intramuscular Injection	7 times transmembrane proteins
	Bacterial toxin
Electrical Pulse Stimulation After Intradermal Injection	Transmembrane proteins, intracellular proteins, etc.
Hydrodynamic Intravenous Injection	Multiple transmembrane transport proteins

█ Advantages of DNA Immunoinduced Production of Monoclonal Antibodies

-- DNA immunization stimulates both humoral and cellular immunity, accelerates the maturation of antigen-specific B-lymphocytes, and thus induces the production of highly specific antibodies that effectively recognize target antigenic epitopes.

-- The target gene is directly introduced into the host cell for expression, thus avoiding the natural conformation and immunogenicity of the protein from being affected by external factors.

-- The ability to design a variety of immunization strategies according to one's own needs during the application process, as well as the ability to select candidates that match the antigenic specificity of the target.

-- It is safer, simpler, more economical and more reliable than traditional immunization methods, and provides a good technical platform for the preparation of high-quality monoclonal antibodies.

█ DNA Immunization Service Process (Virus as Vehicle, Alpaca Nano Antibody Development as an Example)

Service Project	Content	Period
Gene Synthesis	Gene template synthesis, codon optimization, AAV vector construction	4-6 weeks
Animal Immunization	Standard immunization procedure, ELISA for serum potency + FACS serum test	10 weeks
Antibody Screening	Alpaca blood collection, library construction, and screening to obtain VHH antibody sequences	4-6 weeks
Antibody Production	Hybridoma cell production, antibody purification	Selectable

█ Service Advantage

-- No recombinant proteins required, worry-free full-length membrane protein immunization, low cost (compared to VLP), simple and fast

-- Ion channel proteins, multiple transmembrane protein immunizations

-- Generate antibodies with high affinity and specificity;

-- High specificity of target immunization, high purity of mRNA immunizing antigen (compared to cellular immunization)

DNA Immune Antibody Preparation Service Frequently Asked Questions

Q: The low production of antibodies expressed in DNA affects the production and activity of antibodies.

A: Optimize DNA design, including selecting appropriate promoters, signal sequences, and expression vectors; Optimize transfection and culture conditions to improve the transcription and translation efficiency of intracellular DNA; Adopting enhanced expression systems, such as improved plasmid construction techniques or viral vectors.
Q: Antibodies expressed in DNA may not fold and assemble correctly, resulting in structural abnormalities or inactivation.

A: Optimize DNA design to ensure that the antibody structure and sequence encoded by DNA meet the requirements for normal folding and assembly; Use appropriate cell lines and culture conditions to promote the correct folding and assembly of antibodies.
Q: DNA is easily degraded within cells, leading to unstable antibody production.

A: Design DNA sequences with high stability, such as adding appropriate promoters, terminators, and enhancers; Using plasmid stable replication systems or selecting stable cell lines to reduce DNA degradation.
Q: Antibodies expressed in DNA may have immunogenicity, triggering the host's immune response.

A: Select appropriate host cells and expression systems to reduce immunogenicity; When designing DNA, avoid sequences or structures that contain immunogenicity, such as CpG enrichment regions.

Q: The low production of antibodies expressed in DNA affects the production and activity of antibodies.

A: Optimize DNA design, including selecting appropriate promoters, signal sequences, and expression vectors; Optimize transfection and culture conditions to improve the transcription and translation efficiency of intracellular DNA; Adopting enhanced expression systems, such as improved plasmid construction techniques or viral vectors.
Q: Antibodies expressed in DNA may not fold and assemble correctly, resulting in structural abnormalities or inactivation.

A: Optimize DNA design to ensure that the antibody structure and sequence encoded by DNA meet the requirements for normal folding and assembly; Use appropriate cell lines and culture conditions to promote the correct folding and assembly of antibodies.
Q: DNA is easily degraded within cells, leading to unstable antibody production.

A: Design DNA sequences with high stability, such as adding appropriate promoters, terminators, and enhancers; Using plasmid stable replication systems or selecting stable cell lines to reduce DNA degradation.
Q: Antibodies expressed in DNA may have immunogenicity, triggering the host's immune response.

A: Select appropriate host cells and expression systems to reduce immunogenicity; When designing DNA, avoid sequences or structures that contain immunogenicity, such as CpG enrichment regions.

Consult Now DNA Immune Antibody Preparation Service

Animal Immunization Technology Services

Recommended Services

DNA Immune Antibody Preparation Service Frequently Asked Questions

Q: The low production of antibodies expressed in DNA affects the production and activity of antibodies.

Q: Antibodies expressed in DNA may not fold and assemble correctly, resulting in structural abnormalities or inactivation.

Q: DNA is easily degraded within cells, leading to unstable antibody production.

Q: Antibodies expressed in DNA may have immunogenicity, triggering the host's immune response.

Q: The low production of antibodies expressed in DNA affects the production and activity of antibodies.

Q: Antibodies expressed in DNA may not fold and assemble correctly, resulting in structural abnormalities or inactivation.

Q: DNA is easily degraded within cells, leading to unstable antibody production.

Q: Antibodies expressed in DNA may have immunogenicity, triggering the host's immune response.

Consult Now DNA Immune Antibody Preparation Service